Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a mouth rinse save your taste buds during cancer treatment?

NCT ID NCT06500884

Symptom relief Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 28, 2026 · Updated 5 times

Summary

This study tests whether certain mouth rinses or oral medications can prevent or reduce taste changes caused by the drug talquetamab, used to treat multiple myeloma. About 210 participants will be randomly assigned to different preventive treatments. The goal is to find a way to keep patients' sense of taste intact during therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Talquetamab (a drug) and various mouth rinses or oral medications to prevent taste changes
What this could lead to
If successful, this study could identify a way to prevent or reduce the unpleasant taste changes that often come with talquetamab treatment, making it easier for patients to tolerate.
What could go wrong
This is a phase 2 trial, so it's still early. The preventive treatments may not work well for everyone, and taste changes might still occur. The study focuses on managing side effects, not on curing the cancer itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Multiple myeloma (MM) according to IMWG diagnostic criteria * Were triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb) * Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen * Have an Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0 or 1 at screening. Participants with ECOG-PS 2 or 3 are eligible for the study if the ECOG-PS score is related to stable physical limitations (e.g., wheelchair-bound due to prior spinal cord injury) and not related to multiple myeloma or associated therapy * Be willing and able to adhere to the lifestyle restrictions specified in the protocol Exclusion Criteria: * Contraindications or life-threatening known allergies, hypersensitivity, or intolerance to any study drug or its excipients * Stroke, transient ischemic attack, or seizure within 6 months prior to screening * Any of the following within 6 months prior to the first dose of study treatment: severe or unstable angina, myocardial infarction; major thromboembolytic event (e.g., pulmonary embolism, cerebrovascular accident), clinically significant ventricular arrythmia or heart failure New York Heart Association functional classification Class III or IV. Uncomplicated deep vein thrombosis is not considered exclusionary * Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment * A WETT score indicating severe dysgeusia at screening and confirmed prior to randomization. Also unresolved/severe dysgeusia referred by the participant or a finding in the physical examination/oral cavity inspection. Some examples include leukoplakia, prior mouth cancers, extensive dental caries, severe periodontitis, active oral infections, candidiasis, parotic gland removal, or radiotherapy with resultant xerostomia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma Refractory multiple myeloma Relapse multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    37 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Albert Schweitzer Ziekenhuis

    RECRUITING

    Dordrecht, 3318 AT, Netherlands

  • Belfast City Hospital

    RECRUITING

    Belfast, BT9 7AB, United Kingdom

  • Clinica Medica Sao Germano LTDA

    RECRUITING

    São Paulo, 04537 081, Brazil

  • Colchester Hospital University NHS

    RECRUITING

    Colchester, CO4 5JL, United Kingdom

  • Colorado Blood Cancer Institute

    RECRUITING

    Denver, Colorado, 80218, United States

  • Duke University Medical Center

    RECRUITING

    Durham, North Carolina, 27705, United States

  • Eastbourne District General Hospital

    RECRUITING

    Eastbourne, BN21 2UD, United Kingdom

  • Erasmus MC

    RECRUITING

    Rotterdam, 3015 CN, Netherlands

  • Fundacao Universidade de Caxias do Sul

    RECRUITING

    Caxias do Sul, 95070 560, Brazil

  • Hammersmith Hospital

    RECRUITING

    London, W12 0HS, United Kingdom

  • Hosp Clinic de Barcelona

    RECRUITING

    Barcelona, 08036, Spain

  • Hosp Clinico Univ de Salamanca

    RECRUITING

    Salamanca, 37007, Spain

  • Hosp. Quiron Madrid Pozuelo

    RECRUITING

    Pozuelo de Alarcón, 28223, Spain

  • Hosp. Univ. 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hosp. Univ. Germans Trias I Pujol

    RECRUITING

    Badalona, 08916, Spain

  • Hosp. Univ. Ramon Y Cajal

    RECRUITING

    Madrid, 28034, Spain

  • Hosp. Univ. Virgen de La Arrixaca

    RECRUITING

    El Palmar, 30120, Spain

  • Hosp. de Jerez de La Frontera

    RECRUITING

    Jerez de la Frontera, 11407, Spain

  • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer

    RECRUITING

    Curitiba, 81520-060, Brazil

  • Hospital Espanol Auxilio Mutuo Auxilio Mutuo Cancer Center

    RECRUITING

    San Juan, 00918, Puerto Rico

  • IDOR - Regional Bahia

    RECRUITING

    Salvador, 41253-190, Brazil

  • IDOR - Regional Brasilia

    RECRUITING

    Brasília, 70390-140, Brazil

  • IDOR - Regional Sao Paulo

    RECRUITING

    São Paulo, 01401 002, Brazil

  • Icahn School of Medicine at Mt. Sinai

    RECRUITING

    New York, New York, 10029, United States

  • Newcastle Freeman Hospital

    COMPLETED

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • Samsung Medical Center

    RECRUITING

    Seoul, 135-230, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • The Catholic University of Korea Seoul St Mary s Hospital

    RECRUITING

    Seoul, 06591, South Korea

  • The Christie NHS Foundation Trust Christie Hospital

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • The Clatterbridge Cancer Centre

    RECRUITING

    Liverpool, L7 8YA, United Kingdom

  • University College London Hospitals

    RECRUITING

    London, NW1 2BU, United Kingdom

  • University Hospitals Cleveland Medical Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

  • University of Rochester Medical Center

    RECRUITING

    Rochester, New York, 14642, United States

  • University of Washington

    RECRUITING

    Seattle, Washington, 98109, United States

  • VUMC Amsterdam

    RECRUITING

    Amsterdam, 1081 HV, Netherlands

  • Virginia Commonwealth University - Massey Cancer Center

    RECRUITING

    Richmond, Virginia, 23298, United States

  • Yale University School Of Medicine

    RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.